Skip to main content

Table 2 Drug-related adverse events

From: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

Adverse events ICIs maintenance ICIs + Pem maintenance
All
(n = 24)
Grade 1–2
(n = 18)
Grade 3–4
(n = 6)
All
(n = 76)
Grade 1–2
(n = 61)
Grade 3–4
(n = 15)
Hematologic toxicity 7 6 1 19 10 9
Pneumonia 3 2 1 12 7 5
Thyroid/hyperglycemia 2 2 0 6 6 0
Elevated LFTs 2 1 1 2 2 0
Diarrhea or colitis 2 1 1 1 1 0
Fatigue 2 2 0 18 18 0
Skin/rash 5 3 2 3 2 1
Peripheral edema 1 1 0 5 5 0
Decreased appetite 0 0 0 6 6 0
RCCEP 0 0 0 4 4 0
  1. ICIs Immune checkpoint inhibitors, Pem Pemetrexed, LFTs Liver function tests, RCCEP Reactive cutaneous capillary endothelial proliferation